Creating an effective targeted drug involves defining the clinical trial patient cohorts and designing the biomarker profile for the companion diagnostic (CDx)—a lengthy and iterative process that requires extensive research, testing, and refinement.
QIAGEN Real-World Insights (RWI) provides the ability to rapidly mine real-world data and link genomic information to specific phenotypes to design a trial tailored to the desired patient cohort and optimized for the highest likelihood of success.